Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Boehringer Ingelheim acquires Evax AG for equine health

PRIVATEAug 11, 2026•about 3 hours ago

Acquiring Company

Boehringer Ingelheim

Acquired Company

Evax AG

Escambia CountyZurichBiotechnologyHealth Care

Description

Boehringer Ingelheim has acquired Evax AG, enhancing its equine health portfolio. Evax specializes in therapeutic vaccines for horses, targeting allergic skin diseases. This acquisition aims to innovate treatment options and improve health outcomes for equine patients. Terms of the transaction were not disclosed.

Company Information

Company

Boehringer Ingelheim

Location

Escambia County, Alabama, United States

Predictive Intelligence
Strategic

ML-powered predictions for Boehringer Ingelheim's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Evax AG?

Evax AG was acquired by Boehringer Ingelheim, based in Escambia County. The deal was reported on August 11, 2026. Boehringer Ingelheim is privately held.

When did Boehringer Ingelheim acquire Evax AG?

Boehringer Ingelheim's acquisition of Evax AG was reported on August 11, 2026. Boehringer Ingelheim has acquired Evax AG, enhancing its equine health portfolio. Evax specializes in therapeutic vaccines for horses, targeting allergic skin diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Evax AG do?

Evax AG is a Swiss biotech company focused on equine health, particularly in developing therapeutic vaccines for horses. It is privately held, operating in Biotechnology, and is based in Zurich.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.